USA: In patients with advanced pulmonary arterial hypertension (PAH), adding the biologic sotatercept-csrk (Winrevair; Merck) ...

LungFit PH, Beyond Air's nitric oxide therapy device, has received the European CE mark approval for pulmonary hypertension ...

Comparison measures of lung function and improved categorization of cardiovascular disease (CVD) risk were among the key ...

Watch our fascinating panel discussion on managing pulmonary hypertension as an MDT from our Clinical Excellence in ...

Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients ...

Royalty Corporation now owns an economic interest in seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension ...

XOMA Royalty Corp. (XOMA), a biotechnology royalty aggregator, Monday announced that it now owns royalty and milestone interest in ...

Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc., and Chiesi Farmaceutici S.p.A; a Phase 3 study for pulmonary arterial hypertension is ongoing and is expected to read out in ...

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.